Idogen

Mindre end 1K følgere

Idogen (Nasdaq First Growth Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body’s own cells or tissue. The company’s most advanced project, IDO 8, is designed to restore the efficacy of hemophilia drugs in patients who have developed neutralizing antibodies. The company’s second project, IDO T, is being developed to prevent kidney transplant rejection.

Alle

Analyse

Selskabsmeddelelser

ViserAlle indholdstyper

Selskabsmeddelelse6.6.2023, 11.04

Idogen's Board of Directors proposes that liquidation is not to be resolved at the Annual General Meeting on June 8.

Selskabsmeddelelse30.5.2023, 06.03

Idogen working for a sale of its proprietary technology platform

Pressemeddelelse10.5.2023, 06.36

Redeye: Idogen - Q1 2023 – In a tough situation

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto

Følgere og notifikationer om fulgte virksomheder

Analytikerkommentarer og anbefalinger

Værktøj til at sammenligne aktier og andre populære værktøjer

Selskabsmeddelelse28.4.2023, 06.02

Idogen in discussions about a reversed merger. The company intends to add an agenda item at the annual general meeting on June 8 for possible liquidation

Selskabsmeddelelse18.4.2023, 06.01

Idogen is investigating reverse acquisitions to avoid risk of liquidation

Pressemeddelelse27.2.2023, 07.48

Redeye: Idogen Q4 2022 - The future is contingent on funding

Selskabsmeddelelse24.2.2023, 11.04

Idogen publishes interim report for 1 January - 31 December 2022

Pressemeddelelse7.2.2023, 07.22

BioStock: Idogen one of ten companies selected for field-leading event

Pressemeddelelse31.1.2023, 12.17

Idogen invited by GJCF to participate in their 3[rd] Summit for NMOSD Tolerization

Selskabsmeddelelse17.1.2023, 16.31

Idogen announces outcome of rights issue

Pressemeddelelse9.1.2023, 07.03

Last day for subscription of shares in Idogen's rights issue is Friday January 13, 2023

Pressemeddelelse12.12.2022, 07.14

Idogen's first clinical trial, "Toler8", briefly described in Blood

Pressemeddelelse25.11.2022, 07.29

BioStock: Idogen strengthens the Board with Jan Holgersson

Pressemeddelelse14.11.2022, 14.16

Idogen's financial contribution from Horizon 2020 now finalizes with a publication

Selskabsmeddelelse8.11.2022, 17.01

Idogen carries out a rights issue of approximately SEK 43.7 million

Selskabsmeddelelse1.11.2022, 18.16

Agneta Edberg elected as new Chairman of Idogen due to changes to the Board of Directors

Pressemeddelelse17.10.2022, 06.03

Idogen: EU to disburse the remaining MSEK 4.7 of the Horizon grant

Selskabsmeddelelse3.10.2022, 20.07

Idogen sharpens focus on its IDO 8 program and lowers operating expenditure

Selskabsmeddelelse3.10.2022, 16.01

Idogen announces outcome of exercise period for warrants of series TO 5

Pressemeddelelse27.9.2022, 07.51

BioStock: Exciting times for Idogen's new Chairman of the Board

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.